Shattuck Labs Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Portfolio Pulse from Benzinga Insights
Shattuck Labs (NASDAQ:STTK) has received mixed analyst ratings over the past three months, with a notable decrease in the average price target by 18.18%. Analysts have maintained a 'Buy' rating but adjusted price targets, reflecting a cautious outlook. The company, a clinical-stage biotech firm, has shown significant revenue growth but faces challenges with negative net margins and ROA.
August 27, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Shattuck Labs has received mixed analyst ratings, with a decrease in the average price target by 18.18%. Analysts maintain a 'Buy' rating but have adjusted price targets, indicating a cautious outlook. The company shows strong revenue growth but faces challenges with negative net margins and ROA.
The mixed analyst ratings and decrease in price target suggest a cautious outlook for STTK. While the 'Buy' rating is maintained, the adjustments in price targets reflect concerns over financial metrics like negative net margins and ROA, despite strong revenue growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100